Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension (Q70298320)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6356900 AND SRC:MED&resulttype=core&format=json

10 October 2019

title

Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6356900 AND SRC:MED&resulttype=core&format=json

10 October 2019

1

W H Frishman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6356900 AND SRC:MED&resulttype=core&format=json

10 October 2019

author name string

E. L. Michelson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:6356900

6 October 2023

B. F. Johnson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:6356900

6 October 2023

M. P. Poland

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:6356900

6 October 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6356900

6 October 2023

publication date

1 October 1983

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6356900 AND SRC:MED&resulttype=core&format=json

10 October 2019

17 October 1983

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6356900

full work available at URL

6 October 2023

https://api.elsevier.com/content/article/PII:0002934383901377?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

https://api.elsevier.com/content/article/PII:0002934383901377?httpAccept=text/plain

6 October 2023

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

American Journal of Medicine

6 October 2023

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6356900 AND SRC:MED&resulttype=core&format=json

10 October 2019

volume

75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6356900 AND SRC:MED&resulttype=core&format=json

10 October 2019

issue

4A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6356900 AND SRC:MED&resulttype=core&format=json

10 October 2019

page(s)

54-67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6356900 AND SRC:MED&resulttype=core&format=json

Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 3. Comparative clinical experience and new therapeutic applications

10 October 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

6 October 2023

Drug therapy: metoprolol

2

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

beta-Adrenoceptor antagonists: new drugs and new indications

6 October 2023

3

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Selectivity of beta-adrenoceptor agonists and antagonists on bronchial, skeletal, vascular and cardiac muscle in the anaesthetized cat

6 October 2023

4

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: Labetalol

6 October 2023

5

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol

6 October 2023

6

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Labetalol in resistant hypertension

6 October 2023

7

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Labetalol: a review of its pharmacology and therapeutic use in hypertension

6 October 2023

8

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Labetalol therapy in patients with systemic hypertension and angina pectoris: effects of combined alpha and beta adrenoceptor blockade

6 October 2023

9

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Comparison of labetalol with other anti-hypertensive drugs

6 October 2023

10

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Review of long-term treatment with labetalol

6 October 2023

11

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Hemodynamic Changes After Acute and Long-Term Combined Alpha—Beta-Adrenoceptor Blockade with Labetalol as Compared with Beta-Receptor Blockade

6 October 2023

13

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Effect of propranolol and prazosin on blood lipids. The Oslo Study

6 October 2023

14

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Response of the systemic and pulmonary circulation to alpha- and beta-receptor blockade (labetalol) at rest and during exercise in hypertensive patients

6 October 2023

18

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Labetalol in long-term treatment of hypertension

6 October 2023

19

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Controlled comparison of labetalol and propranolol in the management of severe hypertension

6 October 2023

20

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

The beta-adrenoceptor blocking drugs

6 October 2023

21

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects

6 October 2023

22

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Effects of beta-adrenergic blockade during exercise in hypertensive and ischaemic heart-disease

6 October 2023

23

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 2. Physiologic and metabolic effects

6 October 2023

24

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Hypertension: which beta-blocker?

6 October 2023

25

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Control plasma renin activity and changes in sympathetic tone as determinants of minoxidil-induced increase in plasma renin activity

6 October 2023

26

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

The Antidiuretic Action of Diazoxide

6 October 2023

27

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Labetalol in the treatment of severe essential hypertension: relationship between arterial blood pressure, plasma catecholamines, plasma renin activity, plasma aldosterone and body weight

6 October 2023

29

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

Haemodynamic effects of long-term oral labetalol

6 October 2023

30

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

The clinical significance of the plasma high density lipoproteins.

6 October 2023

32

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90137-7

6 October 2023

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6356900 AND SRC:MED&resulttype=core&format=json

10 October 2019

1 reference